Cryton Biosciences

Cryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.

Cryton Biosciences operates in lifetech based in Indianapolis, Indiana.

Profile

Cryton Biosciences is a lifetech company focused on addressing mitochondrial dysfunction, a critical factor in tumor growth and immune cell exhaustion. The company is developing a first-in-class dual-action drug that restores mitochondrial function in both immune and cancer cells, leading to immunogenic tumor death. This approach rewires tumor metabolism to induce stress and cell death while reversing immune exhaustion to enhance anti-cancer activity. The lead drug candidate, CB-101, has demonstrated robust anti-tumor efficacy in preclinical models of colorectal cancer and melanoma, including durable complete responses and enhanced effects when combined with standard chemotherapy. A patient selection strategy has been defined to target populations with high unmet medical needs. Cryton Biosciences has advanced a portfolio of optimized compounds and secured intellectual property protection for its lead chemical series. The company’s innovative dual-action mechanism represents a significant advancement in cancer therapeutics by simultaneously targeting tumor cells and revitalizing immune responses.

As a business in lifetech, Cryton Biosciences is listed here with the public details available about it.

The company is recorded as being based in Indianapolis, Indiana.

It is recorded at the Plug and Play accelerated startup stage.

Website: crytonbio.com